Ronald C Fagan MD, PC
Ronald C Fagan MD, PC was paid $2.37M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoRONALD C FAGAN MD, PC
FARMINGDALE, NY 11735
FARMINGDALE, NY 11735
33aNPI1023146198assigned 03/01/2007
33bProvider typeSpecialist
28Total paid$2.37M
24GClaims86,028
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in New York
Rank by total paid#77 of 1,221
Median peer was paid$45K
This provider vs. median52×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,182 | $74K | |
| 2019 | 6,182 | $136K | |
| 2020 | 10,872 | $258K | |
| 2021 | 20,627 | $491K | |
| 2022 | 18,768 | $494K | |
| 2023 | 16,374 | $561K | |
| 2024incomplete | 10,023 | $358K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 11,994 | 7,962 | $777K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 4,966 | 4,196 | $538K |
| 99442 | 4.6% | 1,467 | 1,125 | $110K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.5% | 514 | 514 | $82K |
| 83970 | 3.1% | 1,841 | 1,829 | $74K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.4% | 1,971 | 1,957 | $56K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.0% | 429 | 428 | $48K |
| 86769 | 2.0% | 1,359 | 1,349 | $48K | |
| 82670 | 1.7% | 1,495 | 1,483 | $41K | |
| 82784 | 1.5% | 1,414 | 1,399 | $37K | |
| 82627 | 1.3% | 1,498 | 1,485 | $31K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.2% | 1,618 | 1,273 | $29K |
94 more codes
| 82728 | <1% | 1,840 | $23K | |
| 82607 | <1% | 1,856 | $22K | |
| 93000 | <1% | 1,595 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 295 | $19K |
| 99401 | <1% | 1,705 | $19K | |
| 82746 | <1% | 1,590 | $18K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,964 | $18K |
| 86141 | <1% | 1,832 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,828 | $17K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 220 | $16K |
| 93880 | <1% | 115 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,807 | $16K |
| 82785 | <1% | 1,336 | $15K | |
| 84439 | <1% | 1,802 | $15K | |
| 84403 | <1% | 585 | $14K | |
| 93975 | <1% | 71 | $14K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $11K |
| 80061 | Lipid panel | <1% | 1,875 | $11K |
| 84480 | <1% | 1,798 | $10K | |
| 93922 | <1% | 153 | $10K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 39 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 24 | $8K |
| 83540 | <1% | 1,853 | $8K | |
| 83735 | <1% | 1,788 | $8K | |
| 86328 | <1% | 248 | $8K | |
| 84681 | <1% | 398 | $8K | |
| 84100 | <1% | 1,718 | $7K | |
| 82977 | <1% | 1,521 | $7K | |
| 84550 | <1% | 1,743 | $7K | |
| 83615 | <1% | 1,531 | $7K | |
| 83550 | <1% | 1,409 | $7K | |
| 86376 | <1% | 461 | $6K | |
| 93015 | <1% | 122 | $6K | |
| 84402 | <1% | 243 | $6K | |
| 84144 | <1% | 291 | $6K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,691 | $6K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 709 | $5K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 40 | $5K |
| 83001 | <1% | 284 | $5K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 37 | $5K |
| 83002 | <1% | 282 | $5K | |
| 84146 | <1% | 256 | $5K | |
| 83525 | <1% | 444 | $5K | |
| 93978 | <1% | 25 | $4K | |
| 84153 | <1% | 176 | $3K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 582 | $3K |
| 86431 | <1% | 358 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 44 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 44 | $1K |
| 83721 | <1% | 1,484 | $1K | |
| 84270 | <1% | 715 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 30 | $959.60 |
| 0011A | <1% | 23 | $959.56 | |
| 95923 | <1% | 12 | $906.80 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 36 | $896.42 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 63 | $859.52 |
| 0012A | <1% | 20 | $834.97 | |
| 96127 | <1% | 270 | $834.82 | |
| 81003 | <1% | 492 | $770.13 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,115 | $682.01 |
| 0013A | <1% | 13 | $565.54 | |
| 86160 | <1% | 28 | $546.00 | |
| 95921 | <1% | 12 | $534.80 | |
| 81005 | <1% | 326 | $490.04 | |
| 81002 | <1% | 254 | $473.47 | |
| 82172 | <1% | 27 | $423.34 | |
| 3074F | <1% | 628 | $417.50 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $361.21 |
| 94010 | <1% | 15 | $331.22 | |
| 3078F | <1% | 505 | $325.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 40 | $231.35 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $220.12 |
| 82962 | <1% | 441 | $175.93 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 2,397 | $142.01 |
| 36000 | <1% | 12 | $100.00 | |
| 3079F | <1% | 79 | $70.00 | |
| 99051 | <1% | 12 | $69.30 | |
| 3075F | <1% | 56 | $42.50 | |
| 83695 | <1% | 58 | $17.18 | |
| 82247 | <1% | 620 | $7.82 | |
| 3288F | 0% | 277 | $0.00 | |
| 4004F | 0% | 98 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 84 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 44 | $0.00 |
| 1159F | 0% | 21 | $0.00 | |
| 1036F | 0% | 221 | $0.00 | |
| 3044F | 0% | 52 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 83 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 17 | $0.00 |
| 3061F | 0% | 14 | $0.00 | |
| 1126F | 0% | 13 | $0.00 | |
| 3008F | 0% | 23 | $0.00 | |
| 1170F | 0% | 14 | $0.00 | |
| 3017F | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFAGAN, RONALD (OWNER /PRESIDENT)